© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Assembly Biosciences, Inc. (ASMB) stock surged +0.80%, trading at $26.54 on NASDAQ, up from the previous close of $26.33. The stock opened at $26.63, fluctuating between $26.30 and $26.67 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 29, 2026 | 26.95 | 28.21 | 25.97 | 26.33 | 65.33K |
| Apr 28, 2026 | 27.52 | 28.25 | 26.83 | 27.00 | 55.46K |
| Apr 27, 2026 | 27.88 | 28.57 | 27.39 | 27.52 | 49.23K |
| Apr 23, 2026 | 28.33 | 28.60 | 27.70 | 28.33 | 78.97K |
| Apr 22, 2026 | 27.40 | 28.89 | 27.25 | 28.30 | 80.12K |
| Apr 21, 2026 | 28.20 | 28.88 | 26.62 | 26.95 | 183.01K |
| Apr 20, 2026 | 29.23 | 29.25 | 27.62 | 28.13 | 96.69K |
| Apr 17, 2026 | 29.91 | 30.19 | 28.80 | 29.24 | 229.83K |
| Apr 16, 2026 | 29.74 | 30.05 | 29.09 | 29.32 | 174.96K |
| Apr 14, 2026 | 29.52 | 30.05 | 29.20 | 29.44 | 81.14K |
| Apr 13, 2026 | 28.32 | 30.14 | 28.32 | 29.24 | 143.17K |
| Apr 10, 2026 | 29.99 | 30.72 | 28.26 | 28.42 | 138.9K |
| Apr 09, 2026 | 29.10 | 30.18 | 29.10 | 29.85 | 113.02K |
| Apr 08, 2026 | 29.72 | 29.83 | 28.82 | 29.35 | 115.75K |
| Apr 07, 2026 | 28.96 | 29.37 | 28.10 | 28.53 | 67.43K |
| Apr 06, 2026 | 29.94 | 30.18 | 29.00 | 29.22 | 114.95K |
| Apr 02, 2026 | 28.63 | 29.75 | 28.40 | 29.01 | 37.86K |
| Apr 01, 2026 | 28.05 | 30.02 | 28.05 | 29.43 | 77.75K |
| Mar 31, 2026 | 27.01 | 28.14 | 26.66 | 27.75 | 97.9K |
| Mar 30, 2026 | 27.84 | 28.12 | 26.32 | 26.64 | 72.6K |
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
| Employees | 73 |
| Beta | 1.16 |
| Sales or Revenue | $7.16M |
| 5Y Sales Change% | 1.41% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |